Casimir Adade Adade, Amine Cheikh, Hafid Mefetah, Amina Kili, Laila Hessissen, Mustapha Bouatia
Casimir Adade Adade*1, Amine Cheikh2, Hafid Mefetah3, Amina Kili4, Laila Hessissen4, Mustapha Bouatia1,3
1Faculty of Medicine and Pharmacy of Rabat, Mohamed V University, 10170 Rabat, Morocco.
2Department of Pharmacy, Faculty of Pharmacy, Abulcasis University, 10000 Rabat, Morocco.
3Department of Pharmacy, Pediatric Hospital, 10170 Rabat, Morocco.
4Pediatric Hematology and Oncology Center, Mohamed V University, 10170 Rabat, Morocco.
Volume - 15,
Issue - 6,
Year - 2022
Objective: To determine the incidence and frequency of adverse drug reactions (ADRs) induced by cancer chemotherapy in pediatric inpatients. Patients and methods: This was a six-month prospective observational study in the pediatric hematology-oncology department of the children's hospital of Rabat. This study took into account ADRs manifested by in inpatient children and undergoing cancer chemotherapy. A modified version of the Moroccan Poison Control and Pharmacovigilance Centre's notification form was used to collect demographic, clinical, cancer treatment and ADR-related data. The causality, severity and preventability were assessed for each adverse event. Results: 106 patients out of 118 followed have developed a total of 266 ADRs. The most frequent ADRs were anemia (14.3%), infections (9.4%), leukopenia (8.6%) and fever (8.3%). Vincristine (16.3%), etoposide (14%) and cytarabine (13%) were the most frequently administered products. Cytarabine followed by etoposide were the drugs most involved in ADRs. The majority of ADRs (55.6%) were probable according to the WHO method of causality assessment. Conclusion: Cancer chemotherapy is associated with a high risk of developing ADRs, particularly hematological ADRs in children. Pediatric patients receiving cytarabine and daunorubicin combinations and regimens including anthracyclines should receive more attention. Risk management plans need to be implemented by health care teams in this area.
Cite this article:
Casimir Adade Adade, Amine Cheikh, Hafid Mefetah, Amina Kili, Laila Hessissen, Mustapha Bouatia. Adverse effects of Anticancer Chemotherapy in Childhood Cancer: A Prospective Study in a Moroccan hospital. Research Journal of Pharmacy and Technology. 2022; 15(6):2559-4. doi: 10.52711/0974-360X.2022.00428
Casimir Adade Adade, Amine Cheikh, Hafid Mefetah, Amina Kili, Laila Hessissen, Mustapha Bouatia. Adverse effects of Anticancer Chemotherapy in Childhood Cancer: A Prospective Study in a Moroccan hospital. Research Journal of Pharmacy and Technology. 2022; 15(6):2559-4. doi: 10.52711/0974-360X.2022.00428 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-6-32
1. Autier P. Increasing incidence of cancer in children and competing risks. The Lancet Oncology. 2018; 19: 1136-7.
2. Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. The Lancet Oncology. 2017; 18: 719-31.
3. Hubbard AK, Spector LG, Fortuna G, Marcotte EL and Poynter JN. Trends in International Incidence of Pediatric Cancers in Children Under 5 Years of Age: 1988-2012. JNCI Cancer Spectr. 2019; 3: pkz007-pkz.
4. WHO Iternational Agency for Research on Cancer. Data visualization tools for exploring the global cancer burden in 2018.
5. Gupta S, Howard S, Hunger S, Antillon F, Metzger M and al. e. Treating Childhood Cancers in Low- and Middle-Income Countries. Washington, DC: World Bank.2015.
6. Ribeiro RC, Steliarova-Foucher E, Magrath I, et al. Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study. The Lancet Oncology. 2008; 9: 721-9.
7. Depasse J, Caniza MA, Quessar A, et al. Infections in hospitalized children and young adults with acute leukemia in Morocco. Pediatric blood & cancer. 2013; 60: 916-22.
8. Saletta F, Seng MS and Lau LMS. Advances in paediatric cancer treatment. Transl Pediatr. 2014; 3: 156-82.
9. Kalyankar T, Butle S and Chamwad G. Application of Nanotechnology in Cancer Treatment. Research Journal of Pharmacy and Technology. 2012; 5: 1161-7.
10. Jisha K, Venkateswaramurthy N and Sambathkumar R. The Influence of Pharmacogenetics in Cancer Chemotherapy. Research Journal of Pharmacology and Pharmacodynamics. 2020; 12: 29-33.
11. Yadav AR and Mohite SK. Cancer-A Silent Killer: An Overview. Asian Journal of Pharmaceutical Research. 2020; 10: 213-6.
12. Nikam NR, Vakhariya RR and Magdum C. Pharmacovigilance: An Overview. Asian Journal of Research in Pharmaceutical Science. 2019; 9: 107-11.
13. Kengar MD, Patole KK, Ade AK, Kumbhar SM, Patil CD and Ganjave AR. Introduction to Pharmacovigilance and Monitoring. Asian Journal of Pharmaceutical Research. 2019; 9: 116-22.
14. Rajput MD, Rajput Y and Rajput L. A Review on Adverse Drug Reaction. Asian Journal of Pharmaceutical Research. 2020; 10: 221-5.
15. Naik SA. Review on Pharmacovigilance. Asian Journal of Pharmaceutical Research. 2020; 10: 123-8.
16. Andrade PHS, Santos AdS, Souza CAS, Lobo IMF and da Silva WB. Risk factors for adverse drug reactions in pediatric inpatients: a systematic review. Ther Adv Drug Saf. 2017; 8: 199-210.
17. Smyth RMD, Gargon E, Kirkham J, et al. Adverse drug reactions in children--a systematic review. PLoS One. 2012; 7: e24061-e.
18. Saranya P. Pharmacovigilance-An Overview in a Pharmacist Perspective. Research Journal of Pharmacy and Technology. 2020; 13: 3941-6.
19. Lau PM, Stewart K and Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2004; 12: 626-33.
20. Anekha A, Juno JJ, Jayaram S and Neethu Fathima U. Identification and analysis of adverse drug reactions associated with cancer chemotherapy in hospitalized patients. International Journal of Pharmacy and Pharmaceutical Sciences. 2016; 8.
21. Sharma A, Kumari KM, Manohar HD, Bairy KL and Thomas J. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India. Perspectives in clinical research. 2015; 6: 109-15.
22. Chopra D, Rehan HS, Sharma V and Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. Indian journal of medical and paediatric oncology: official journal of Indian Society of Medical & Paediatric Oncology. 2016; 37: 42-6.
23. Hasan MK, Ghareeb MM, Mate BF and Aga QAIAK. Clinical adverse effects of Chemotherapy protocolusing 6-Mercaptopurine in Iraqi patients with Acute Lymphocytic Leukemia during Maintenance Phase. Research Journal of Pharmacy and Technology. 2019; 12: 5757-64.
24. van den Anker J, Reed MD, Allegaert K and Kearns GL. Developmental Changes in Pharmacokinetics and Pharmacodynamics. Journal of clinical pharmacology. 2018; 58 Suppl 10: S10-S25.
25. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M and Ramos JT. Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults. Pharmaceutics. 2011; 3: 53-72.
26. McPhillips H, Stille C, Smith D and al. e. Methodological Challenges in Describing Medication Dosing Errors in Children. Rockville Agency for Healthcare Research and Quality, 2005.
27. Rieder M and Ferro A. Adverse drug reactions. Br J Clin Pharmacol. 2015; 80: 613-4.
28. de Anda-Jáuregui G, Guo K and Hur J. Network-Based Assessment of Adverse Drug Reaction Risk in Polypharmacy Using High-Throughput Screening Data. International Journal of Molecular Sciences. 2019; 20: 386.
29. World Health Organization. The use of the WHO-UMC system for standardised case causality assessment. 2018.
30. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). 2017.
31. Hartwig SC, Siegel J and Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. American journal of hospital pharmacy. 1992; 49: 2229-32.
32. Schumock GT and Thornton JP. Focusing on the preventability of adverse drug reactions. Hospital pharmacy. 1992; 27: 538.
33. Opanga L, Mulaku MN, Opanga SA, Godman B and Kurdi A. Adverse effects of chemotherapy and their management in Pediatric patients with Non-Hodgkin’s Lymphoma in Kenya: A descriptive, situation analysis study. Expert Review of Anticancer Therapy. 2019; 19: 423-30.
34. Prasad A, Datta PP, Bhattacharya J, Pattanayak C, Chauhan AS and Panda P. Pattern of Adverse Drug Reactions Due to Cancer Chemotherapy in a Tertiary Care Teaching Hospital in Eastern India. J Pharmacovigilance. 2013; 1: 107.
35. Shrestha S, Shakya R, Shrestha S and Shakya S. Adverse Drug Reaction due to Cancer Chemotherapy and its Financial Burden in Different Hospitals of Nepal. International Journal of Pharmacovigilance. 2017; 2: 1-7.
36. Abubakar AR, Simbak NB and Haque M. Adverse drug reactions: predisposing factors, modern classifications and causality assessment. Research Journal of Pharmacy and Technology. 2014; 7: 1091-8.
37. Tazi MA, Er-Raki A and Benjaafar N. Cancer incidence in Rabat, Morocco: 2006-2008. Ecancermedicalscience. 2013; 7: 338-.
38. La Fondation Lalla Salma. Registre des Cancers de la Région du Grand Casablanca 2008-2012 [French]. 2016.
39. Force LM, Abdollahpour I, Advani SM, et al. The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. The Lancet Oncology. 2019; 20: 1211-25.
40. Wahlang JB, Laishram PD, Brahma DK, Sarkar C, Lahon J and Nongkynrih BS. Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Ther Adv Drug Saf. 2017; 8: 61-6.
41. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. British journal of haematology. 2008; 141: 840-7.
42. Deley M-CL, Paulussen M, Lewis I, et al. Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. Journal of Clinical Oncology. 2014; 32: 2440-8.
43. Electronic Medicines Compendium and UK. Vincristine Sulfate: Summary of Product Characteristics. electronic medicines compendium UK, 2007.
44. Electronic Medicines Compendium and UK. Cytarabine: Summary of Product Characteristics. electronic medicines compendium UK, 1999.
45. Malk SA, Kili A, El Kababri M, Hessissen L, El Khorassani M and Khattab M. Neutropénie fébrile chimio-induite : expérience d’un centre d’hématologie et d’oncologie pédiatrique. Journal Africain du Cancer / African Journal of Cancer. 2013; 5: 68-72.